# GALAHAD (NCT02854436)

> An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

No report yet. It can be ordered.

- Drugs tested: niraparib
- Indication: metastatic castration-resistant prostate cancer with DNA-repair gene defects

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02854436
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Janssen Research & Development, LLC
- Conditions: Prostatic Neoplasms
- Interventions: Niraparib
- Enrollment: 289
- Primary outcome: Objective Response Rate (ORR) for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Breast Cancer Gene (BRCA) Mutation

## Indexed commentary on GALAHAD so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- Podcasts: 7
- X threads: 4

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=galahad-nct02854436

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02854436", "email": "<work email>"}; the inbox owner confirms by the emailed link.